Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients with Peritoneal Metastases from Colorectal Cancer

• Status: RECRUITING
• Trial end date: 2026-01-31

Summary

This phase I trial tests the safety, side effects, and best dose of intraperitoneal oxaliplatin and fluorouracil in treating patients with colorectal cancer that has spread to the peritoneal cavity (peritoneal metastasis). Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Fluorouracil stops cells from making DNA and it may kill cancer cells. Both oxaliplatin and fluorouracil are approved by the Food and Drug Administration to treat patients with colorectal cancer, however administration of these drugs directly into the area between the muscles and organs in the abdomen (intraperitoneal) for the treatment of peritoneal metastases is experimental. Giving oxaliplatin and fluorouracil directly into the peritoneal space may be a safe and effective way of treating patients with peritoneal metastases from colorectal cancer.

• Phase: PHASE1

Details

• Lead Sponsor: Arjun Mittra
• Collaborator: National Cancer Institute (NCI)
• Treatments: Biopsy; dehydroftorafur; Fluorouracil; Laparoscopy; Magnetic Resonance Spectroscopy; Oxaliplatin; Specimen Handling; Surgical Procedures, Operative